TTUHSC School of Pharmacy
HomeSOPFaculty & Staff Directory

Faculty & Staff Details






Profile for Vardan Karamyan, PhD

Vardan Karamyan

Vardan Karamyan, PhD

  • Assistant Professor Pharmaceutical Sci Ama
Office Phone: 806-356-4015 ext 286
Email: vardan.karamyan@ttuhsc.edu
Mail Address: 1300 S Coulter St
Amarillo TX 79106-1712

Biography

Dr. Karamyan joined the Department of Pharmaceutical Sciences in August 2008. He received his Doctor of Pharmacy (Magna cum laude) from the Faculty of Pharmacy, Yerevan State Medical University, Armenia, and Ph.D. in Biology from the Institute of Biochemistry, National Academy of Sciences, Yerevan, Armenia. He continued his postdoctoral training in the laboratory of Dr. Robert C. Speth at the Department of Pharmacology in the School of Pharmacy, University of Mississippi.

Research Interests

Our group is studying the (patho)physiological function of metalloendopeptidase neurolysin (EC 3.4.24.16) in ischemic stroke and neurogenic hypertension.


Additionally, in collaboration with Dr. Thomas Abbruscato we study the role of opioid receptors for neuroprotection in stroke. This project involves (patho)physiological and pharmacological studies to understand alterations of opioid receptors in pathophysiology of stroke, and development of new opioid ligands (in collaboration with medicinal chemists) to target these receptors.

Selected Publications:

  • Wangler NJ, Santos KL, Schadock I, Hagen FK, Escher E, Bader M, Speth RC, Karamyan VT. Identification of membrane-bound variant of metalloendopeptidase neurolysin (EC 3.4.24.16) as the non-angiotensin type 1 (non-AT1), non-AT2 angiotensin binding site. J Biol Chem. 2012;287(1):114-22.
  • Tadevosyan A, MacLaughlin EJ, Karamyan VT. Angiotensin II type 1 receptor antagonists in the treatment of hypertension in elderly patients – focus on patient outcomes. Patient Relat Outcome Meas. 2011;2:27-39.
  • Yang L, Shah K, Wang H, Karamyan VT, Abbruscato TJ. Characteriztion of the effects of biphalin, an opioid receptor agonist, in a model of focal brain ischemia.. J. Pharmacol. Exp. Ther.. 2011;(339(2)):499-508.
  • Rashid M, Arumugam TV, Karamyan VT. Association of the novel non-AT1, non-AT2 angiotensin binding site with neuronal cell death.. J Pharmacol Exp Ther. 2010;335(3):754-61.
  • Mizuno CS, Chittiboyina AG, Shah FH, Patny A, Kurtz TW, Pershadsingh HA, Speth RC, Karamyan VT, Carvalho PB, Avery MA. Design, Synthesis, and Docking Studies of Novel Benzimidazoles for the Treatment of Metabolic Syndrome.. J Med Chem. 2010;53(3):1076-85.
©